Misrepair in Context: TGFβ Regulation of DNA Repair

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Genomic integrity is crucial for tissue function and cancer therapy response.
• Transforming growth factor-beta (TGFβ) is a key cytokine in the tumor microenvironment.
• Head and neck squamous cell carcinoma (HNSCC) serves as a model to study TGFβ's role in therapy.

Purpose of the Study:

• To investigate the role of TGFβ signaling in DNA damage repair and therapeutic response in cancer.
• To explore how human papilloma virus (HPV) infection, which impairs TGFβ signaling, affects cancer cell DNA repair mechanisms.
• To determine the potential of TGFβ inhibition as a therapeutic strategy.

Main Methods:

• Comparative analysis of DNA double-strand break (DSB) repair pathways (homologous recombination vs. alternative end-joining) in HPV-positive and HPV-negative HNSCC.
• Assessment of cancer cell sensitivity to radiotherapy, cisplatin, and PARP inhibitors following TGFβ signaling blockade.
• Utilizing HPV infection as a natural model for TGFβ pathway impairment.

Main Results:

• HPV infection in HNSCC significantly impairs TGFβ signaling.
• TGFβ pathway blockade shifts cancer cells from error-free homologous recombination to error-prone alternative end-joining (altEJ) DNA repair.
• Cells utilizing altEJ exhibit increased sensitivity to radiotherapy, cisplatin, and PARP inhibitors.

Conclusions:

• Impairment of TGFβ signaling, as seen in HPV-positive HNSCC, promotes a DNA repair phenotype that sensitizes cancer cells to standard therapies.
• TGFβ inhibitors represent a promising therapeutic strategy for enhancing the efficacy of existing cancer treatments.
• Targeting TGFβ signaling offers a rational approach for improving patient outcomes in HNSCC and potentially other cancers.